Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL. Chris Anzalone. It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

Good mental health (MH) and psychological well-being are fundamental human concerns in determining human happiness and flourishing, both in private and working life. One of the most comprehensive and ...

By Melissa Bianchi, Alyssa Golay, & Scott Loughlin. Alyssa Golay From startups to multinationals, the value of data continues to grow for pharma, biotechs, and device companies. While the value has ...